US Congress House Bill 2562 (Prior Session Legislation)

---

Spectrum: Partisan Bill (Republican 1-0)
Status: Introduced on May 19 2017 - 25% progression, died in committee
Action: 2017-05-26 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]

Making Pharmaceutical Markets More Competitive Act This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to prioritize the review of generic drug applications and supplements with respect to drugs that are in a shortage or for which there are not more than three approved drugs. The holder of an approved drug application must notify the FDA within 180 days of withdrawing or transferring the application or withdrawing the drug from sale. The FDA must maintain a list of generic drugs with three or fewer holders of approved applications.

Making Pharmaceutical Markets More Competitive Act

Rep. Mike Kelly [R-PA]

Date	Chamber	Action
2017-05-26	House	Referred to the Subcommittee on Health.
2017-05-19	House	Referred to the House Committee on Energy and Commerce.
2017-05-19	House	Introduced in House

SB934 (Related) 2017-05-11 - Placed on Senate Legislative Calendar under General Orders. Calendar No. 76.
SB1115 (Same As) 2017-05-11 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Type	Source
Summary	https://www.congress.gov/bill/115th-congress/house-bill/2562/all-info
Text	https://www.congress.gov/115/bills/hr2562/BILLS-115hr2562ih.pdf